How can health-affecting individual lifestyle factors affect the risk of developing acute pancreatitis?

ISRCTN ISRCTN25940508
DOI https://doi.org/10.1186/ISRCTN25940508
Secondary identifying numbers V1
Submission date
15/10/2018
Registration date
22/01/2019
Last edited
05/01/2024
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Acute pancreatitis (AP) is a sudden inflammation of the pancreas (an organ near the stomach that produces substances that aid digestion). AP is painful and can be life-threatening. It needs to be treated in hospital. This study aims to understand the lifestyle factors that increase or reduce the chance of developing AP. This knowledge could be used to suggest changes in lifestyle to help prevent AP in people who are at risk and to reduce the risk of AP or reduce its severity in people who have already had an episode of AP.

Who can participate?
1. People who have had AP in four groups relating to the possible cause of AP: gallstones, hypertriglyceridemia (high levels of fat in the blood), high alcohol intake, other (cystic fibrosis, injury, viral infection etc).
2. People who have not had AP but have one of the possible causes of AP: gallstones, hypertriglyceridemia (high levels of fat in the blood), high alcohol intake, other (cystic fibrosis, injury, viral infection etc).
3. People who are in hospital for reasons other than internal medicine disorders.
4. Healthy people who are not in hospital and have not had AP.

What does the study involve?
All participants will complete questionnaires about their socioeconomic factors (for example income level, social standing) and lifestyle (including dietary habits, physical activity, stress levels and sleep quality) covering the last year and the last month. The questionnaires will take about 2 hours to complete and trained administrators will help the participants to complete them.

What are the possible benefits and risks of participating?
There are no benefits and risks in participating in this study.

Where is the study run from?
The University of Pécs Medical School Institute for Translational Medicine (Hungary).

When is the study starting and how long is it expected to run for?
August 2018 to June 2026

Who is funding the study?
The University of Pécs, Medical School

Who is the main contact?
Andrea Szentesi, Study Coordinator, Institute for Translational Medicine, Medical School, University of Pécs
szentesiai@gmail.com

Study website

Contact information

Prof Péter Hegyi
Scientific

Szigeti str. 12.
Pécs
H-7624
Hungary

ORCiD logoORCID ID 0000-0003-0399-7259
Phone +36 72 536250
Email hegyi.peter@pte.hu

Study information

Study designProspective observational multicentre case-control study.
Primary study designObservational
Secondary study designCase-control study
Study setting(s)Hospital
Study typePrevention
Participant information sheet Not available in web format, please use contact details to request a participant information sheet.
Scientific titleLIFEStyle, Prevention and risk of Acute paNcreatitis (LIFESPAN): Protocol of a prospective, multicentre and multinational observational case-control study
Study acronymLIFESPAN
Study objectivesThe main goal of our study is to determine negative or positive associations between socio-economic factors, dietary habits, physical activity, chronic stress and sleep quality and acute pancreatitis. This would enable us to suggest lifestyle modifications for patients discharged from the hospitals after AP or for those who wish to reduce their risk for AP.
Ethics approval(s)

Approved 31/10/2018, Secretary of Medical Research Council Scientific and Research Ethics Committee (Pf.: 314., Budapest, 1903, Hungary; +36 1 795-1197; tukeb@bm.gov.hu), ref: 54175-2/2018/EKU

Health condition(s) or problem(s) studiedAcute pancreatitis
InterventionLIFESPAN is an observational study, therefore there is no intervention performed. Participants who fulfill the inclusion criteria will be asked to spend approximately 2 hours answering a complex questionnaire about their lifestyle and medical history. The questions cover eating and sleeping habits, physical activity, stress levels and socioeconomic status. We are going to ask the same questions concerning the last year and the last month. There is no follow-up in this study. The applied questionnaires are validated. Trained administrators will help the participants to complete them.
Every patient suffering from AP will have the opportunity to take part in the case group of the study. According to the etiology of the AP (alcoholic, biliary, hypertriglyceridemia or other), four subgroups will be formed. The four subgroups will be matched with the following control groups: (a) patients with alcoholic or biliary or hypertriglyceridemia background with no AP, (b) patients suffering from acute diseases other than internal medicine associated diseases and (c) healthy subjects.
Intervention typeBehavioural
Primary outcome measure1. Personal details and physical and socioeconomic status assessed using questions from the National Health and Nutrition Examination Survey (NHANES 2015-16), the American Community Survey (ACS) and the MacArthur Scale of Subjective Social Status.
2. Medical history assessed using the Acute Pancreatitis Questionnaire (Registry for Pancreatic Patients by Hungarian Pancreatic Study Group).
3. Dietary habits assessed using the Diet History Questionnaire, Version 2.0.
4. Physical activity assessed using the International Physical Activity Questionnaire (IPAQ, long, usual-week version) .
5. Stress levels assessed using the Perceived Stress Scale (10-item version).
6. Sleep quality assessed using the Pittsburgh Sleep Quality Index.
All these questionnaires were completed on the day of recruitment. Participants filled in two of each questionnaire - one covering the last year and one covering the last month.

7. Characteristics of acute AP assessed using the Acute Pancreatitis Questionnaire was filled out once by the AP participants only.
Secondary outcome measuresN/A
Overall study start date01/08/2018
Completion date30/06/2026

Eligibility

Participant type(s)Mixed
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants3900, including 1700 patients in the AP group and 2200 subjects in the control groups
Key inclusion criteriaPatients with acute pancreatitis (AP):
1. Aged over 18 years
2. Diagnosed AP on the basis of the “2 out of 3” rules of the IAP/APA guideline: (a) upper abdominal pain; (b) serum amylase or lipase >3x upper limit of normal range; (c) characteristic findings on pancreatic imaging
3. Written informed consent form is signed.

Patients with AP in alcohol etiology group:
4. Patients consuming >5 drinks per day or >35 drinks per week for both sexes [= 8.75 units per day; 61.25 units per week] shall be included. Please note that 1 unit of alcohol = 10 ml or 8 g of pure (100%) alcohol.

Patients with AP in gallstone etiology group:
5. Presence of gallstone (not sludge).

Patients with AP in hypertriglyceridemia etiology group:
6. Triglyceride level in blood over 11 mmol/l.

Patients with AP in ‘other’ etiology group:
7. The causative agents do not match either of the first 3 groups, AP is induced by e.g.: endoscopic retrograde cholangiopancreatography (ERCP) (post-ERCP pancreatitis), virus infection, trauma, medicine (drug-induced pancreatitis), congenital anatomical malformation, cystic fibrosis, genetics, gluten sensitive enteropathy etc.

Control groups (Patients with no AP history):
8. Aged over 18 years
9. Absence of AP at present as well as in the medical history
10. Written informed consent form is signed

Control patients in alcohol group:
11. Patients consuming >5 drinks per day or >35 drinks per week for both sexes [= 8.75 units per day; 61.25 units per week] shall be included. Please note that 1 unit of alcohol = 10 ml or 8g of pure (100%) alcohol.

Control patients in gallstone group:
12. Presence of gallstone (not sludge).

Control patients in hypertrigliceridaemia group:
13. Triglyceride level over 11 mmol/l.

Control patients in hospital-based control group:
14. Hospital admissions in Traumatology, Ophthalmic Department, etc.

15. Control patients in population-based control group
Key exclusion criteria1. Patients do not have reliable information or data.
2. Patients unlikely to adhere to study requirements.
Date of first enrolment01/04/2019
Date of final enrolment31/12/2025

Locations

Countries of recruitment

  • Hungary
  • Romania

Study participating centres

Institute for Translational Medicine, Medical School, University of Pécs
Szigeti út 12.
Pécs
H-7624
Hungary
Department of Medicine, University of Szeged
Kálvária sgt. 57
Szeged
H-6725
Hungary
University of Debrecen
Egyetem tér 1.
Debrecen
H-4032
Hungary
Szent György Teaching Hospital of Fejér County
Seregélyesi u. 3.
Székesfehérvár
H-8000
Hungary
Institute of Pancreatic Diseases, Semmelweis University
Tömő u. 25-29
Budapest
H-1083
Hungary
County Emergency Clinical Hospital of Târgu Mures - Gastroenterology Clinic and University of Medicine, Pharmacy, Sciences and Technology "George Emil Palade"
Strada Gheorghe Marinescu 50
Targu Mures
540136
Romania

Sponsor information

University of Pécs Medical School, Momentum Grant of the Hungarian Academy of Sciences
University/education

LP2014-10/2014
Pécs
H-7624
Hungary

Phone +36 72 536250
Email hegyi.peter@pte.hu
Economic Development and Innovation Operative Programme Grant and Highly Cited Publication Grant of the National Research, Development and Innovation Office
Government

GINOP-2.3.2-15-2016-00048 'Stay Alive', KH-125578 and EFOP 3.6.2-16-2017-00006 'Live Longer'
Pécs
H-7624
Hungary

Phone +36 72 536250
Email hegyi.peter@pte.hu
Translational Medicine Foundation
Hospital/treatment centre

Pálfy str. 52/D
Szeged
H-6725
Hungary

Phone +36 72 536250
Email hegyi.peter@pte.hu
Hungarian Academy of Sciences
Government

Funders

Funder type

University/education

Általános Orvostudományi Kar, Pécsi Tudományegyetem
Government organisation / Local government
Alternative name(s)
Medizinische Fakultät, Universität Pécs, PTE Általános Orvostudományi Kar, Medizinische Fakultät, Universität Pécs, Medical School, University of Pécs, ÁOK, PTE, UP MS, PTE ÁOK
Location
Hungary

Results and Publications

Intention to publish date30/06/2026
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planWe plan to publish the results in a Q1 high-quality international journal.
IPD sharing planThe study data will be available upon request from the principal investigator (Prof. Péter Hegyi, Institute of Translational Medicine, University of Pécs, Medical School, hegyi.peter@pte.hu). The questionnaires, the eCFR (raw data) and the analyzed data can be available for other laboratories' reasonable use following a personal request.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article 06/01/2020 05/01/2024 Yes No

Editorial Notes

05/01/2024: The following changes were made:
1. Publication reference added.
2. Other was replaced by prevention as a study type.
3. The recruitment end date was changed from 30/11/2023 to 31/12/2025.
4. Romania was added as a country of recruitment.
5. The overall study end date was changed from 28/02/2024 to 30/06/2026.
6. The Institute of Pancreatic Diseases, Semmelweis University and County Emergency Clinical Hospital of Târgu Mures - Gastroenterology Clinic and University of Medicine, Pharmacy, Sciences and Technology "George Emil Palade" were added as study participating centres.
7. The intention to publish date was changed from 30/06/2024 to 30/06/2026.